A post hoc analysis of the Reduction of Endpoints in Non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial showed that approximately 15% of losartan’s renal protective effect is attributed to the decrease in serum UA levels33. Here, AGT is linked to type 1 diabetes mellitus.